All In Biotech

Drug Trial Radar · NCT06621654

Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

A Randomized, Partially Blinded, Positively Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine in a Population Aged 2 Months and Older

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Actual

Start

Nov 15, 2024

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 months, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of age groups, from the oldest to the youngest, and the initial safety assessment will be conducted on the 8th day after the first dose of vaccination for each age group, and the next group will be enrolled only after the safety is confirmed.

Conditions

  • Haemophilus Influenzae Type B Infection

Interventions

  • Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological

    1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

  • Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological

    1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

  • Haemophilus Influenzae Type b Conjugate VaccineBiological

    1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

  • Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological

    3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection

  • Haemophilus Influenzae Type b Conjugate VaccineBiological

    3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection

  • Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological

    4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection

  • Haemophilus Influenzae Type b Conjugate VaccineBiological

    4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age. Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse reactions in all subjectsTime frame: Within 30 days of each dose of vaccine

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiulongpo District Center for Disease Control and Prevention

    Chongqing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.